TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical firm at the forefront of enhancing cancer therapy through its proprietary localized drug delivery systems, which significantly improve the effectiveness of immuno-oncology agents. The company is strategically addressing the complexities of tumor microenvironments with a robust pipeline of clinical programs aimed at advancing treatment options in oncology. With a commitment to expanding patient access to transformative therapies, TriSalus is well-positioned to drive meaningful change in cancer care, aligning with the growing demand for advanced, effective cancer treatments. The company’s initiatives underscore its potential to be a key player in the rapidly evolving oncology landscape, attracting interest from both investors and healthcare stakeholders.
| Revenue (TTM) | $45.08M |
| Gross Profit (TTM) | $38.67M |
| EBITDA | $-29.95M |
| Operating Margin | -86.00% |
| Return on Equity | -496.20% |
| Return on Assets | -36.70% |
| Revenue/Share (TTM) | $0.90 |
| Book Value | $0.11 |
| Price-to-Book | 49.35 |
| Price-to-Sales (TTM) | 7.20 |
| EV/Revenue | 6.91 |
| EV/EBITDA | -5.96 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1.70% |
| Shares Outstanding | $61.58M |
| Float | $49.50M |
| % Insiders | 33.96% |
| % Institutions | 35.81% |
Volatility is currently expanding
TriSalus Life Sciences NASDAQ: TLSI outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity's Global Growth Conference, with management emphasizing the company's pressure-enabled delivery technology for solid-tumor treatments.
TriSalus Life Sciences NASDAQ: TLSI reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increased. The company reiterated its full-year 2026 revenue outlook of $54 million to $57 million, representing projected growth of 19% to 26% over 2025.
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the Canaccord Genuity 46th Annual Growth Conference. Management will participate in one-on-one meetings o.
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2026. A press release detailing the.
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ: TLSI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ: TLSI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOS ANGELES, June 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TriSalus Life Sciences, Inc. (“TriSalus” or “the Company”) (NASDAQ: TLSI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TriSalus Life Sciences, Inc. ("TriSalus" or "the Company") (NASDAQ: TLSI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ: TLSI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TLSI and any ticker you trade — then tracks every position and per-strategy win rate.
